Cargando…
Update on infections caused by Stenotrophomonas maltophilia with particular attention to resistance mechanisms and therapeutic options
Stenotrophomonas maltophilia is a Gram-negative, biofilm-forming bacterium. Although generally regarded as an organism of low virulence, S. maltophilia is an emerging multi-drug resistant opportunistic pathogen in hospital and community settings, especially among immunocompromised hosts. Risk factor...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4557615/ https://www.ncbi.nlm.nih.gov/pubmed/26388847 http://dx.doi.org/10.3389/fmicb.2015.00893 |
_version_ | 1782388513650507776 |
---|---|
author | Chang, Ya-Ting Lin, Chun-Yu Chen, Yen-Hsu Hsueh, Po-Ren |
author_facet | Chang, Ya-Ting Lin, Chun-Yu Chen, Yen-Hsu Hsueh, Po-Ren |
author_sort | Chang, Ya-Ting |
collection | PubMed |
description | Stenotrophomonas maltophilia is a Gram-negative, biofilm-forming bacterium. Although generally regarded as an organism of low virulence, S. maltophilia is an emerging multi-drug resistant opportunistic pathogen in hospital and community settings, especially among immunocompromised hosts. Risk factors associated with S. maltophilia infection include underlying malignancy, cystic fibrosis, corticosteroid or immunosuppressant therapy, the presence of an indwelling central venous catheter and exposure to broad spectrum antibiotics. In this review, we provide a synthesis of information on current global trends in S. maltophilia pathogenicity as well as updated information on the molecular mechanisms contributing to its resistance to an array of antimicrobial agents. The prevalence of S. maltophilia infection in the general population increased from 0.8–1.4% during 1997–2003 to 1.3–1.68% during 2007–2012. The most important molecular mechanisms contributing to its resistance to antibiotics include β-lactamase production, the expression of Qnr genes, and the presence of class 1 integrons and efflux pumps. Trimethoprim/sulfamethoxazole (TMP/SMX) is the antimicrobial drug of choice. Although a few studies have reported increased resistance to TMP/SMX, the majority of studies worldwide show that S. maltophilia continues to be highly susceptible. Drugs with historically good susceptibility results include ceftazidime, ticarcillin-clavulanate, and fluoroquinolones; however, a number of studies show an alarming trend in resistance to those agents. Tetracyclines such as tigecycline, minocycline, and doxycycline are also effective agents and consistently display good activity against S. maltophilia in various geographic regions and across different time periods. Combination therapies, novel agents, and aerosolized forms of antimicrobial drugs are currently being tested for their ability to treat infections caused by this multi-drug resistant organism. |
format | Online Article Text |
id | pubmed-4557615 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-45576152015-09-18 Update on infections caused by Stenotrophomonas maltophilia with particular attention to resistance mechanisms and therapeutic options Chang, Ya-Ting Lin, Chun-Yu Chen, Yen-Hsu Hsueh, Po-Ren Front Microbiol Public Health Stenotrophomonas maltophilia is a Gram-negative, biofilm-forming bacterium. Although generally regarded as an organism of low virulence, S. maltophilia is an emerging multi-drug resistant opportunistic pathogen in hospital and community settings, especially among immunocompromised hosts. Risk factors associated with S. maltophilia infection include underlying malignancy, cystic fibrosis, corticosteroid or immunosuppressant therapy, the presence of an indwelling central venous catheter and exposure to broad spectrum antibiotics. In this review, we provide a synthesis of information on current global trends in S. maltophilia pathogenicity as well as updated information on the molecular mechanisms contributing to its resistance to an array of antimicrobial agents. The prevalence of S. maltophilia infection in the general population increased from 0.8–1.4% during 1997–2003 to 1.3–1.68% during 2007–2012. The most important molecular mechanisms contributing to its resistance to antibiotics include β-lactamase production, the expression of Qnr genes, and the presence of class 1 integrons and efflux pumps. Trimethoprim/sulfamethoxazole (TMP/SMX) is the antimicrobial drug of choice. Although a few studies have reported increased resistance to TMP/SMX, the majority of studies worldwide show that S. maltophilia continues to be highly susceptible. Drugs with historically good susceptibility results include ceftazidime, ticarcillin-clavulanate, and fluoroquinolones; however, a number of studies show an alarming trend in resistance to those agents. Tetracyclines such as tigecycline, minocycline, and doxycycline are also effective agents and consistently display good activity against S. maltophilia in various geographic regions and across different time periods. Combination therapies, novel agents, and aerosolized forms of antimicrobial drugs are currently being tested for their ability to treat infections caused by this multi-drug resistant organism. Frontiers Media S.A. 2015-09-02 /pmc/articles/PMC4557615/ /pubmed/26388847 http://dx.doi.org/10.3389/fmicb.2015.00893 Text en Copyright © 2015 Chang, Lin, Chen and Hsueh. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Public Health Chang, Ya-Ting Lin, Chun-Yu Chen, Yen-Hsu Hsueh, Po-Ren Update on infections caused by Stenotrophomonas maltophilia with particular attention to resistance mechanisms and therapeutic options |
title | Update on infections caused by Stenotrophomonas maltophilia with particular attention to resistance mechanisms and therapeutic options |
title_full | Update on infections caused by Stenotrophomonas maltophilia with particular attention to resistance mechanisms and therapeutic options |
title_fullStr | Update on infections caused by Stenotrophomonas maltophilia with particular attention to resistance mechanisms and therapeutic options |
title_full_unstemmed | Update on infections caused by Stenotrophomonas maltophilia with particular attention to resistance mechanisms and therapeutic options |
title_short | Update on infections caused by Stenotrophomonas maltophilia with particular attention to resistance mechanisms and therapeutic options |
title_sort | update on infections caused by stenotrophomonas maltophilia with particular attention to resistance mechanisms and therapeutic options |
topic | Public Health |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4557615/ https://www.ncbi.nlm.nih.gov/pubmed/26388847 http://dx.doi.org/10.3389/fmicb.2015.00893 |
work_keys_str_mv | AT changyating updateoninfectionscausedbystenotrophomonasmaltophiliawithparticularattentiontoresistancemechanismsandtherapeuticoptions AT linchunyu updateoninfectionscausedbystenotrophomonasmaltophiliawithparticularattentiontoresistancemechanismsandtherapeuticoptions AT chenyenhsu updateoninfectionscausedbystenotrophomonasmaltophiliawithparticularattentiontoresistancemechanismsandtherapeuticoptions AT hsuehporen updateoninfectionscausedbystenotrophomonasmaltophiliawithparticularattentiontoresistancemechanismsandtherapeuticoptions |